Alkem Laboratories Sees Significant Open Interest Surge Amid Rising Market Activity

Open Interest and Volume Dynamics

On 23 Feb 2026, Alkem Laboratories recorded an open interest (OI) of 20,287 contracts, up from 17,449 the previous session, marking an absolute increase of 2,838 contracts. This 16.26% rise in OI was accompanied by a robust volume of 17,259 contracts, indicating that fresh positions are being established rather than existing ones being squared off. The futures segment alone accounted for a value of approximately ₹44,059 lakhs, while options contributed a staggering ₹7,275 crores in notional value, underscoring the stock’s prominence in the derivatives market.

The underlying stock price closed at ₹5,466, outperforming its sector by 0.96% and the Sensex by 1.11% on the day. Notably, Alkem has been on a two-day winning streak, delivering cumulative returns of 1.69%, signalling positive investor sentiment. The stock’s delivery volume surged to 1.86 lakh shares on 20 Feb, a 45.16% increase over the five-day average, reflecting rising investor participation in the cash market as well.

Market Positioning and Directional Bets

The sharp increase in open interest alongside rising volumes suggests that market participants are actively building positions, possibly anticipating further upside in Alkem Laboratories. The stock’s current trading levels are above its 5-day and 200-day moving averages, although it remains below the 20-day, 50-day, and 100-day averages, indicating a mixed technical picture. This positioning often attracts short- to medium-term traders looking to capitalise on momentum while remaining cautious of longer-term resistance levels.

Given the pharmaceutical sector’s ongoing resilience and Alkem’s mid-cap status with a market capitalisation of ₹65,396 crores, investors appear to be balancing growth prospects with valuation considerations. The MarketsMOJO Mojo Score for Alkem stands at 52.0, with a Hold rating, recently downgraded from Buy on 1 Dec 2025. This reflects a tempered outlook amid sectoral headwinds and competitive pressures, yet the stock’s liquidity and rising delivery volumes continue to support active trading interest.

Implications of Rising Open Interest

Open interest is a critical barometer of market conviction. The 16.26% increase in Alkem’s OI, coupled with rising volumes, indicates that fresh capital is flowing into the stock’s derivatives, signalling confidence in its near-term prospects. This contrasts with scenarios where volume rises but OI declines, which typically suggest position unwinding.

Investors and traders often interpret such OI surges as a sign of directional bets being placed. In Alkem’s case, the positive price action and rising delivery volumes imply that the majority of these bets are bullish. However, the stock’s Hold rating and Mojo Grade of 52.0 counsel caution, suggesting that while momentum is building, risks remain from sectoral volatility and valuation pressures.

Technical and Fundamental Context

Technically, Alkem’s price is comfortably above its 5-day and 200-day moving averages, which often act as support levels. However, resistance near the 20-day and 50-day averages could cap gains in the short term. The stock’s liquidity profile is robust, with an average traded value sufficient to support trade sizes of nearly ₹2 crore, making it attractive for institutional and retail traders alike.

Fundamentally, Alkem operates in the Pharmaceuticals & Biotechnology sector, which continues to attract investor interest due to steady demand and innovation pipelines. Despite a recent downgrade from Buy to Hold by MarketsMOJO on 1 Dec 2025, the company’s mid-cap stature and market cap grade of 2 reflect a stable but cautious investment stance. The downgrade likely factors in competitive pressures and margin challenges, but the stock’s recent outperformance relative to sector and benchmark indices highlights its resilience.

Investor Takeaway and Outlook

For investors, the surge in open interest and volume in Alkem Laboratories’ derivatives signals a renewed interest in the stock’s potential upside. The current momentum, supported by rising delivery volumes and outperformance against sector and benchmark indices, suggests that market participants are positioning for further gains.

However, the Hold rating and moderate Mojo Score advise a balanced approach. Investors should monitor key technical levels, sector developments, and quarterly earnings updates to gauge sustainability of the current trend. The stock’s liquidity and active derivatives market provide ample opportunities for tactical trading, but longer-term investors may prefer to weigh alternative mid-cap pharmaceutical names with stronger ratings and fundamentals.

Overall, Alkem Laboratories remains a stock to watch closely as open interest trends often presage significant price moves. The current data points to a cautiously optimistic market stance, with directional bets favouring upside but tempered by valuation and sector risks.

Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →